Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.92 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.92 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.85 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.55 |
| ▸ | PDE4A | P27815 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | TOP1 | P11387 | 1/20 | 0.37 |
| ▸ | MGAM | O43451 | 2/20 | 0.34 |
| ▸ | SI | P14410 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mannitol SCHEMBL9755015 | 1.00 | LMNA (0.92) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL13187369 | 0.96 | LMNA (1.00) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL2477078 | 0.96 | LMNA (1.00) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL2297640 | 0.96 | LMNA (1.00) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL20594082 | 0.96 | LMNA (1.00) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL23066399 | 0.96 | LMNA (1.00) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Sorbitol SCHEMBL763 | 0.96 | LMNA (1.00) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL21837180 | 0.96 | LMNA (1.00) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL20594083 | 0.96 | LMNA (1.00) | LMNAL3MBTL1TDP1KDM4EPDE4A | |
| Mannitol SCHEMBL20567656 | 0.96 | LMNA (1.00) | LMNAL3MBTL1TDP1KDM4EPDE4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 196 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210038500-A1 | DICLOFENAC AND HYALURONIC ACID COMBINATION TREATMENT FOR ORAL LEUKPOPLAKIA | EHRENPREIS ELI D (US) | 2021-02-11 | — | — | US | claimed |
| WO-2020160344-A1 | DICLOFENAC AND HYALURONIC ACID COMBINATION TREATMENT FOR ORAL LEUKPOPLAKIA | EHRENPREIS ELI D (US) | 2020-08-06 | — | — | WO | claimed |
| US-20200179268-A1 | DICLOFENAC AND HYALURONIC ACID COMBINATION TREATMENT FOR ORAL LEUKPOPLAKIA | GI PHARMACEUTICALS, INC. AKS E2BIO CONSULTANTS | 2020-06-11 | — | — | US | claimed |
| CN-102320869-B | Potassium sorbitol liquid fertilizer | JIANGMEN YINGHAO AGRICULTURAL TECHNOLOGY CO., LTD. (CN) | 2014-10-29 | — | — | CN | claimed |
| EP-2489638-B1 | APPARATUS FOR REDUCING WASTE LITHOGRAPHIC PRINTING PLATE DEVELOPING LIQUID | FUJIFILM GLOBAL GRAPHIC SYSTEMS CO LTD (JP) | 2014-07-23 | — | — | EP | claimed |
| EP-2489638-A1 | APPARATUS FOR REDUCING WASTE LITHOGRAPHIC PRINTING PLATE DEVELOPING LIQUID | Fujifilm Graphic Systems Co., Ltd. (JP) | 2012-08-22 | — | — | EP | claimed |
| US-7319032-B2 | Non-sugar sweeteners for use in test devices | MEDTOX (US) | 2008-01-15 | — | — | US | claimed |
| US-7285426-B2 | Bulking materials containing starch reagent for use in test devices | MEDTOX SCIENTIFIC, INC. (US) | 2007-10-23 | — | — | US | claimed |
| WO-2006036212-A2 | NON-SUGAR SWEETENERS FOR USE IN TEST DEVICES | MEDTOX SCIENTIFIC, INC. (US) | 2006-04-06 | — | — | WO | claimed |
| US-20050255608-A1 | Bulking materials containing starch reagent for use in test devices | MEDTOX SCIENTIFIC, INC. (US) | 2005-11-17 | — | — | US | claimed |
| US-20050239214-A1 | Non-sugar sweeteners for use in test devices | MEDTOX SCIENTIFIC, INC. (US) | 2005-10-27 | — | — | US | claimed |
| WO-1999005987-A1 | TOOTH WHITENING SYSTEM | ANDERSON MICHAEL R (US) | 1999-02-11 | — | — | WO | claimed |
| EP-3266457-B1 | BILE ACID RECYCLING INHIBITORS FOR TREATMENT OF PEDIATRIC CHOLESTATIC LIVER DISEASES | SHIRE HUMAN GENETIC THERAPIES (US) | 2026-05-06 | — | — | EP | disclosed |
| EP-4424363-B1 | METHODS FOR INCREASING GROWTH IN PEDIATRIC SUBJECTS HAVING CHOLESTATIC LIVER DISEASE | MIRUM PHARMACEUTICALS INC (US) | 2026-04-29 | — | — | EP | disclosed |
| US-12599602-B2 | Methods for treating cholestasis | MIRUM PHARMACEUTICALS, INC. | 2026-04-14 | — | — | US | disclosed |
| US-12576079-B2 | Methods for treating cholestasis | MIRUM PHARMACEUTICALS, INC. | 2026-03-17 | — | — | US | disclosed |
| US-5965191-A | TREATING WITH SALT AND AN ALKALI MATERIAL | KABUSHIKI KAISHA KATAYAMA (JP) | 1999-10-12 | — | — | US | disclosed |
| WO-1999012521-A1 | NEW FOAM-FORMING PHARMACEUTICAL COMPOSITION | ASTRA AKTIEBOLAG (SE) | 1999-03-18 | — | — | WO | disclosed |
| WO-1999005987-A1 | TOOTH WHITENING SYSTEM | ANDERSON MICHAEL R (US) | 1999-02-11 | — | — | WO | disclosed |
| EP-0813821-A1 | PROCESSED FISH MEAT, FISH MEAT MATERIAL PREPARED BY USING THE SAME, AND PROCESS FOR PRODUCING PROCESSED FISH MEAT | Kabushiki Kaisha Katayama (JP) | 1997-12-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12599602-B2 | Methods for treating cholestasis | SLC10A1, SLC10A2, SLC10A6 | LMNA 3099/4885L3MBTL1 3109/4885TDP1 3996/4885 |
| US-12576079-B2 | Methods for treating cholestasis | SLC10A1, SLC10A2, SLC10A6 | LMNA 2963/4885L3MBTL1 1199/4885TDP1 4586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.